Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of 177Lu-Based Radiopharmaceuticals. Read more about Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of 177Lu-Based Radiopharmaceuticals.
Reply to "Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals". Read more about Reply to "Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals".
Proceedings: PET Drugs-A 2023 Workshop on Product Quality, Regulatory Submissions, Facility Inspections, and Benefit-Risk Considerations. Read more about Proceedings: PET Drugs-A 2023 Workshop on Product Quality, Regulatory Submissions, Facility Inspections, and Benefit-Risk Considerations.
Imaging Efficacy of [18F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study. Read more about Imaging Efficacy of [18F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath-A Phase 3, Prospective Multicenter Study.
Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study. Read more about Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study.
Dual-Tracer Imaging on a Long-Axial-Field-of-View PET: A Proof-of-Principle Study with [18F]FGln and [18F]FDG. Read more about Dual-Tracer Imaging on a Long-Axial-Field-of-View PET: A Proof-of-Principle Study with [18F]FGln and [18F]FDG.
Evaluation of 134Ce/134La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer. Read more about Evaluation of 134Ce/134La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer.
FDA Reconsiders Rules Around Radiation Dosimetry for First-in-Human Studies of Investigational PET Radiopharmaceuticals. Read more about FDA Reconsiders Rules Around Radiation Dosimetry for First-in-Human Studies of Investigational PET Radiopharmaceuticals.
Funding Reductions Threaten the Future of Medical Innovation. Read more about Funding Reductions Threaten the Future of Medical Innovation.
Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data. Read more about Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data.
